Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis

This phase II #ClinicalTrial reports that #Camrelizumab + #Apatinib and #Chemotherapy yields high response rates & manageable safety in #TNBC, with #Biomarker analyses enabling prediction & evaluation of treatment efficacy. #Medsky
#STTT #OpenAccess: doi.org/10.1038/s413...

Findings from the randomized ATTENTION #ClinicalTrial demonstrate that #Aumolertinib plus #Apatinib significantly improves progression-free survival with manageable safety in treatment-naïve, #EGFR-mutant advanced #NSCLC.

#STTT #OpenAccess: doi.org/10.1038/s413...

A phase II #ClinicalTrial—evaluating #Aumolertinib + #Apatinib vs. aumolertinib monotherapy—revealed a manageable safety profile with improved progression-free survival in untreated, #EGFR-mutant, advanced #NSCLC patients.

#STTT #OpenAccess: doi.org/10.1038/s413...

Fluzoparib + Apatinib: 11 meses vs 3 en cáncer mama metastásico BRCA (FABULOUS Lancet)

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#CancerDeMama #BRCA #Fluzoparib #Apatinib #FABULOUS #Oncologia #LancetOncology

Combining #camrelizumab and #apatinib with #chemotherapy showed strong efficacy, manageable toxicity, and robust immune activation, highlighting its promise as an effective #NeoadjuvantTherapy. #medsky

#OpenAccess in #STTT: doi.org/10.1038/s413...

This study shows that #camrelizumab plus #apatinib with SOX, followed by maintenance treatment, achieved favorable survival outcomes, highlighting this combination as a promising treatment option in AFP-G/GEJ #adenocarcinoma. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

Phase 2 NeoSAC trial showed that the addition of #apatinib to sintilimab and carboplatin-nab-paclitaxel #chemotherapy improves clinical efficacy, with a manageable safety profile in early triple-negative #BreastCancer (#TNBC). #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

Could third time be the charm for a Chinese manufactured IO drug? #camrelizumab apparently on track for ⁦@US_FDA⁩ review based on 1L Ph3 data in #HCC in combination with TKI #apatinib #HCCTwitter ...